
UndisclosedBioTech
Excalipoint Raises $68.7M for T Cell Engager Development
•March 18, 2026
•Mar 18, 2026
Participants
Deal Summary
Shanghai-based biotech Excalipoint announced it has raised $68.7 million to advance its T cell engager platform. The funding will support the development of next‑generation immunotherapies. Investors were not disclosed.
Comments
Want to join the conversation?
Loading comments...